1
|
Tarjányi O, Haerer J, Vecsernyés M, Berta G, Stayer-Harci A, Balogh B, Farkas K, Boldizsár F, Szeberényi J, Sétáló G. Prolonged treatment with the proteasome inhibitor MG-132 induces apoptosis in PC12 rat pheochromocytoma cells. Sci Rep 2022; 12:5808. [PMID: 35388084 PMCID: PMC8987075 DOI: 10.1038/s41598-022-09763-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Accepted: 03/29/2022] [Indexed: 11/09/2022] Open
Abstract
Rat pheochromocytoma (PC12) cells were treated with the proteasome inhibitor MG-132 and morphological changes were recorded. Initially, neuronal differentiation was induced but after 24 h signs of morphological deterioration became apparent. We performed nuclear staining, flow cytometry and WST-1 assay then analyzed signal transduction pathways involving Akt, p38 MAPK (Mitogen-Activated Protein Kinase), JNK (c-Jun N-terminal Kinase), c-Jun and caspase-3. Stress signaling via p38, JNK and c-Jun was active even after 24 h of MG-132 treatment, while the survival-mediating Akt phosphorylation declined and the executor of apoptosis (caspase-3) was activated by that time and apoptosis was also observable. We examined subcellular localization of stress signaling components, applied kinase inhibitors and dominant negative H-Ras mutant-expressing PC12 cells in order to decipher connections of stress-mediating pathways. Our results are suggestive of that treatment with the proteasome inhibitor MG-132 has a biphasic nature in PC12 cells. Initially, it induces neuronal differentiation but prolonged treatments lead to apoptosis.
Collapse
Affiliation(s)
- Oktávia Tarjányi
- Department of Medical Biology and Central Electron Microscope Laboratory, University of Pécs, Medical School, Szigeti út 12., Pecs, 7624, Hungary.,Signal Transduction Research Group, János Szentágothai Research Centre, Ifjúság útja 20., Pecs, 7624, Hungary
| | - Julian Haerer
- Department of Medical Biology and Central Electron Microscope Laboratory, University of Pécs, Medical School, Szigeti út 12., Pecs, 7624, Hungary
| | - Mónika Vecsernyés
- Department of Medical Biology and Central Electron Microscope Laboratory, University of Pécs, Medical School, Szigeti út 12., Pecs, 7624, Hungary.,Signal Transduction Research Group, János Szentágothai Research Centre, Ifjúság útja 20., Pecs, 7624, Hungary
| | - Gergely Berta
- Department of Medical Biology and Central Electron Microscope Laboratory, University of Pécs, Medical School, Szigeti út 12., Pecs, 7624, Hungary.,Signal Transduction Research Group, János Szentágothai Research Centre, Ifjúság útja 20., Pecs, 7624, Hungary
| | - Alexandra Stayer-Harci
- Department of Medical Biology and Central Electron Microscope Laboratory, University of Pécs, Medical School, Szigeti út 12., Pecs, 7624, Hungary.,Signal Transduction Research Group, János Szentágothai Research Centre, Ifjúság útja 20., Pecs, 7624, Hungary
| | - Bálint Balogh
- Department of Medical Biology and Central Electron Microscope Laboratory, University of Pécs, Medical School, Szigeti út 12., Pecs, 7624, Hungary
| | - Kornélia Farkas
- Institute of Bioanalysis, University of Pécs, Medical School, Szigeti út 12., Pecs, 7624, Hungary
| | - Ferenc Boldizsár
- Department of Immunology and Biotechnology, University of Pécs, Medical School, Szigeti út 12., Pecs, 7624, Hungary
| | - József Szeberényi
- Department of Medical Biology and Central Electron Microscope Laboratory, University of Pécs, Medical School, Szigeti út 12., Pecs, 7624, Hungary.,Signal Transduction Research Group, János Szentágothai Research Centre, Ifjúság útja 20., Pecs, 7624, Hungary
| | - György Sétáló
- Department of Medical Biology and Central Electron Microscope Laboratory, University of Pécs, Medical School, Szigeti út 12., Pecs, 7624, Hungary. .,Signal Transduction Research Group, János Szentágothai Research Centre, Ifjúság útja 20., Pecs, 7624, Hungary.
| |
Collapse
|
2
|
Masternak J, Gilewska A, Kowalik M, Kazimierczuk K, Sitkowski J, Okła K, Wietrzyk J, Barszcz B. Synthesis, crystal structure and spectroscopic characterization of new anionic iridium(III) complexes and their interaction with biological targets. Polyhedron 2022. [DOI: 10.1016/j.poly.2022.115837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
3
|
Cáceres-Gutiérrez RE, Andonegui MA, Oliva-Rico DA, González-Barrios R, Luna F, Arriaga-Canon C, López-Saavedra A, Prada D, Castro C, Parmentier L, Díaz-Chávez J, Alfaro-Mora Y, Navarro-Delgado EI, Fabian-Morales E, Tran B, Shetty J, Zhao Y, Alcaraz N, De la Rosa C, Reyes JL, Hédouin S, Hubé F, Francastel C, Herrera LA. Proteasome inhibition alters mitotic progression through the upregulation of centromeric α-Satellite RNAs. FEBS J 2021; 289:1858-1875. [PMID: 34739170 PMCID: PMC9299679 DOI: 10.1111/febs.16261] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Revised: 09/19/2021] [Accepted: 11/03/2021] [Indexed: 12/14/2022]
Abstract
Cell cycle progression requires control of the abundance of several proteins and RNAs over space and time to properly transit from one phase to the next and to ensure faithful genomic inheritance in daughter cells. The proteasome, the main protein degradation system of the cell, facilitates the establishment of a proteome specific to each phase of the cell cycle. Its activity also strongly influences transcription. Here, we detected the upregulation of repetitive RNAs upon proteasome inhibition in human cancer cells using RNA‐seq. The effect of proteasome inhibition on centromeres was remarkable, especially on α‐Satellite RNAs. We showed that α‐Satellite RNAs fluctuate along the cell cycle and interact with members of the cohesin ring, suggesting that these transcripts may take part in the regulation of mitotic progression. Next, we forced exogenous overexpression and used gapmer oligonucleotide targeting to demonstrate that α‐Sat RNAs have regulatory roles in mitosis. Finally, we explored the transcriptional regulation of α‐Satellite DNA. Through in silico analyses, we detected the presence of CCAAT transcription factor‐binding motifs within α‐Satellite centromeric arrays. Using high‐resolution three‐dimensional immuno‐FISH and ChIP‐qPCR, we showed an association between the α‐Satellite upregulation and the recruitment of the transcription factor NFY‐A to the centromere upon MG132‐induced proteasome inhibition. Together, our results show that the proteasome controls α‐Satellite RNAs associated with the regulation of mitosis.
Collapse
Affiliation(s)
- Rodrigo E Cáceres-Gutiérrez
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - Marco A Andonegui
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - Diego A Oliva-Rico
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - Rodrigo González-Barrios
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - Fernando Luna
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - Cristian Arriaga-Canon
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - Alejandro López-Saavedra
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - Diddier Prada
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico.,Departamento de Informática Biomédica, Faculty of Medicine, UNAM, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - Clementina Castro
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - Laurent Parmentier
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - José Díaz-Chávez
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - Yair Alfaro-Mora
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - Erick I Navarro-Delgado
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - Eunice Fabian-Morales
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
| | - Bao Tran
- NCI CCR Sequencing Facility, Frederick National Laboratory for Cancer Research, MD, USA
| | - Jyoti Shetty
- NCI CCR Sequencing Facility, Frederick National Laboratory for Cancer Research, MD, USA
| | - Yongmei Zhao
- NCI CCR Sequencing Facility, Frederick National Laboratory for Cancer Research, MD, USA
| | - Nicolas Alcaraz
- The Bioinformatics Centre, University of Copenhagen, Copenhagen, Denmark.,National Institute of Genomic Medicine, Mexico City, Mexico
| | - Carlos De la Rosa
- Departamento de Biología Molecular de Plantas, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico
| | - José L Reyes
- Departamento de Biología Molecular de Plantas, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico
| | - Sabrine Hédouin
- Epigenetics and Cell Fate, CNRS UMR7216, Université de Paris, Paris, France
| | - Florent Hubé
- Epigenetics and Cell Fate, CNRS UMR7216, Université de Paris, Paris, France
| | - Claire Francastel
- Epigenetics and Cell Fate, CNRS UMR7216, Université de Paris, Paris, France
| | - Luis A Herrera
- Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico.,Dirección General, Instituto Nacional de Medicina Genómica, Mexico City, Mexico
| |
Collapse
|
4
|
Uysal S, Soyer Z, Saylam M, Tarikogullari AH, Yilmaz S, Kirmizibayrak PB. Design, synthesis and biological evaluation of novel naphthoquinone-4-aminobenzensulfonamide/carboxamide derivatives as proteasome inhibitors. Eur J Med Chem 2020; 209:112890. [PMID: 33039723 DOI: 10.1016/j.ejmech.2020.112890] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Revised: 09/23/2020] [Accepted: 09/24/2020] [Indexed: 10/23/2022]
Abstract
A series of novel 4-aminobenzensulfonamide/carboxamide derivatives bearing naphthoquinone pharmacophore were designed, sythesized and evaluated for their proteasome inhibitory and antiproliferative activities against human breast cancer cell line (MCF-7). The structures of the synthesized compounds were confirmed by spectral and elemental analyses. The proteasome inhibitory activity studies were carried out using cell-based assay. The antiproteasomal activity results revealed that most of the compounds exhibited inhibitory activity with different percentages against the caspase-like (C-L, β1 subunit), trypsin-like (T-L, β2 subunit) and chymotrypsin-like (ChT-L, β5 subunit) activities of proteasome. Among the tested compounds, compound 14 bearing 5-chloro-2-pyridyl ring on the nitrogen atom of sulfonamide group is the most active compound in the series and displayed higher inhibition with IC50 values of 9.90 ± 0.61, 44.83 ± 4.23 and 22.27 ± 0.15 μM against ChT-L, C-L and T-L activities of proteasome compared to the lead compound PI-083 (IC50 = 12.47 ± 0.21, 53.12 ± 2.56 and 26.37 ± 0.5 μM), respectively. The antiproliferative activity was also determined by MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay in vitro. According to the antiproliferative activity results, all of the compounds exhibited cell growth inhibitory activity in a range of IC50 = 1.72 ± 0.14-20.8 ± 0.5 μM and compounds 13 and 28 were found to be the most active compounds with IC50 values of 1.79 ± 0.21 and 1.72 ± 0.14 μM, respectively. Furthermore, molecular modeling studies were carried out for the compounds 13, 14 and 28 to investigate the ligand-enzyme binding interactions.
Collapse
Affiliation(s)
- Sirin Uysal
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, İzmir, Turkey
| | - Zeynep Soyer
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, İzmir, Turkey.
| | - Merve Saylam
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İzmir Katip Celebi University, İzmir, Turkey
| | - Ayse H Tarikogullari
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, İzmir, Turkey
| | - Sinem Yilmaz
- Department of Biotechnology, Institute of Science, Ege University, İzmir, Turkey; Department of Bioengineering, Faculty of Engineering, University of Alaaddin Keykubat, Antalya, Turkey
| | | |
Collapse
|
5
|
Abstract
The ubiquitin proteasome system (UPS) plays a critical function in cellular homeostasis. The misregulation of UPS is often found in human diseases, including cancer. Kelch-like protein 6 (KLHL6) is an E3 ligase gene mutated in diffused large B-cell lymphoma (DLBCL). This review discusses the function of KLHL6 as a cullin3-RING ligase and how cancer-associated mutations disrupt the interaction with the cullin3, resulting in the loss of KLHL6 function. Furthermore, the mRNA decay factor Roquin2 is discussed as the first bona fide substrate of KLHL6 in the context of B-cell receptor activation and B-cell lymphoma. Importantly, the tumor-suppressing mechanism of KLHL6 via the degradation of Roquin2 and the mRNA decay in the context of the NF-κB pathway is summarized.
Collapse
Affiliation(s)
- Jaewoo Choi
- a Department of Cancer Biology , University of Pennsylvania , Philadelphia , PA , USA ; Perelman School of Medicine and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA
| | - Nan Zhou
- a Department of Cancer Biology , University of Pennsylvania , Philadelphia , PA , USA ; Perelman School of Medicine and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA
| | - Luca Busino
- a Department of Cancer Biology , University of Pennsylvania , Philadelphia , PA , USA ; Perelman School of Medicine and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
6
|
Khalil R, Kenny C, Hill RS, Mochida GH, Nasir RH, Partlow JN, Barry BJ, Al-Saffar M, Egan C, Stevens CR, Gabriel SB, Barkovich AJ, Ellison JW, Al-Gazali L, Walsh CA, Chahrour MH. PSMD12 haploinsufficiency in a neurodevelopmental disorder with autistic features. Am J Med Genet B Neuropsychiatr Genet 2018; 177:736-745. [PMID: 30421579 PMCID: PMC6261799 DOI: 10.1002/ajmg.b.32688] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Revised: 07/23/2018] [Accepted: 09/26/2018] [Indexed: 12/20/2022]
Abstract
Protein homeostasis is tightly regulated by the ubiquitin proteasome pathway. Disruption of this pathway gives rise to a host of neurological disorders. Through whole exome sequencing (WES) in families with neurodevelopmental disorders, we identified mutations in PSMD12, a core component of the proteasome, underlying a neurodevelopmental disorder with intellectual disability (ID) and features of autism spectrum disorder (ASD). We performed WES on six affected siblings from a multiplex family with ID and autistic features, the affected father, and two unaffected mothers, and a trio from a simplex family with one affected child with ID and periventricular nodular heterotopia. We identified an inherited heterozygous nonsense mutation in PSMD12 (NM_002816: c.367C>T: p.R123X) in the multiplex family and a de novo nonsense mutation in the same gene (NM_002816: c.601C>T: p.R201X) in the simplex family. PSMD12 encodes a non-ATPase regulatory subunit of the 26S proteasome. We confirm the association of PSMD12 with ID, present the first cases of inherited PSMD12 mutation, and demonstrate the heterogeneity of phenotypes associated with PSMD12 mutations.
Collapse
Affiliation(s)
- Raida Khalil
- Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas, USA
- Department of Biotechnology and genetic engineering, University of Philadelphia, Amman, Jordan
| | - Connor Kenny
- Division of Genetics and Genomics, Department of Medicine, Boston Children’s Hospital, Boston, Massachusetts, USA
- Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - R. Sean Hill
- Division of Genetics and Genomics, Department of Medicine, Boston Children’s Hospital, Boston, Massachusetts, USA
- Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Ganeshwaran H. Mochida
- Division of Genetics and Genomics, Department of Medicine, Boston Children’s Hospital, Boston, Massachusetts, USA
- Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, Massachusetts, USA
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA
- Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Ramzi H. Nasir
- Division of Genetics and Genomics, Department of Medicine, Boston Children’s Hospital, Boston, Massachusetts, USA
- Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Jennifer N. Partlow
- Division of Genetics and Genomics, Department of Medicine, Boston Children’s Hospital, Boston, Massachusetts, USA
- Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, Massachusetts, USA
- Howard Hughes Medical Institute, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Brenda J. Barry
- Division of Genetics and Genomics, Department of Medicine, Boston Children’s Hospital, Boston, Massachusetts, USA
- Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, Massachusetts, USA
- Howard Hughes Medical Institute, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Muna Al-Saffar
- Division of Genetics and Genomics, Department of Medicine, Boston Children’s Hospital, Boston, Massachusetts, USA
- Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, Massachusetts, USA
- Department of Paediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Chloe Egan
- Division of Genetics and Genomics, Department of Medicine, Boston Children’s Hospital, Boston, Massachusetts, USA
- Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Christine R. Stevens
- Program in Medical and Population Genetics, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA
| | - Stacey B. Gabriel
- Program in Medical and Population Genetics, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA
| | - A. James Barkovich
- Benioff Children’s Hospital, Departments of Radiology, Pediatrics, Neurology, and Neurological Surgery, University of California San Francisco, San Francisco, USA
| | - Jay W. Ellison
- The Permanente Medical Group, San Francisco, California, USA
| | - Lihadh Al-Gazali
- Department of Paediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Christopher A. Walsh
- Division of Genetics and Genomics, Department of Medicine, Boston Children’s Hospital, Boston, Massachusetts, USA
- Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, Massachusetts, USA
- Howard Hughes Medical Institute, Boston Children’s Hospital, Boston, Massachusetts, USA
- Harvard Medical School, Boston, Massachusetts, USA
| | - Maria H. Chahrour
- Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas, USA
- Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, Texas, USA
- Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA
- Correspondence to: Maria Chahrour, PhD, Eugene McDermott Center for Human Growth and Development, Department of Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8591, Phone: (214) 648-6523, Fax: (214) 648-1666,
| |
Collapse
|
7
|
Jorda R, Dušek J, Řezníčková E, Pauk K, Magar PP, Imramovský A, Kryštof V. Synthesis and antiproteasomal activity of novel O -benzyl salicylamide-based inhibitors built from leucine and phenylalanine. Eur J Med Chem 2017; 135:142-158. [DOI: 10.1016/j.ejmech.2017.04.027] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 04/07/2017] [Accepted: 04/09/2017] [Indexed: 10/19/2022]
|
8
|
McDaniel TJ, Lansdell TA, Dissanayake AA, Azevedo LM, Claes J, Odom AL, Tepe JJ. Substituted quinolines as noncovalent proteasome inhibitors. Bioorg Med Chem 2016; 24:2441-2450. [PMID: 27112450 PMCID: PMC5724766 DOI: 10.1016/j.bmc.2016.04.005] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Revised: 03/23/2016] [Accepted: 04/01/2016] [Indexed: 01/26/2023]
Abstract
Screening of a library of diverse heterocyclic scaffolds identified substituted quinolines as inhibitors of the human proteasome. The heterocyclic library was prepared via a novel titanium-catalyzed multicomponent coupling reaction, which rendered a diverse set of isoxazoles, pyrimidines, pyrroles, pyrazoles and quinolines. SAR of the parent lead compound indicated that hydrophobic residues on the benzo-moiety significantly improved potency. Lead compound 25 inhibits the chymotryptic-like proteolytic activity of the proteasome (IC50 5.4μM), representing a new class of nonpeptidic, noncovalent proteasome inhibitors.
Collapse
Affiliation(s)
- Tanner J McDaniel
- Department of Chemistry, Michigan State University, East Lansing, MI 48824, United States
| | - Theresa A Lansdell
- Department of Chemistry, Michigan State University, East Lansing, MI 48824, United States
| | - Amila A Dissanayake
- Department of Chemistry, Michigan State University, East Lansing, MI 48824, United States
| | - Lauren M Azevedo
- Department of Chemistry, Michigan State University, East Lansing, MI 48824, United States
| | - Jacob Claes
- Department of Chemistry, Michigan State University, East Lansing, MI 48824, United States
| | - Aaron L Odom
- Department of Chemistry, Michigan State University, East Lansing, MI 48824, United States.
| | - Jetze J Tepe
- Department of Chemistry, Michigan State University, East Lansing, MI 48824, United States.
| |
Collapse
|
9
|
Tsukamoto S, Takeuchi T, Kawabata T, Kato H, Yamakuma M, Matsuo K, El-Desoky AH, Losung F, Mangindaan REP, de Voogd NJ, Arata Y, Yokosawa H. Halenaquinone inhibits RANKL-induced osteoclastogenesis. Bioorg Med Chem Lett 2014; 24:5315-7. [PMID: 25278237 DOI: 10.1016/j.bmcl.2014.09.043] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Revised: 09/10/2014] [Accepted: 09/16/2014] [Indexed: 10/24/2022]
Abstract
Halenaquinone was isolated from the marine sponge Petrosia alfiani as an inhibitor of osteoclastogenic differentiation of murine RAW264 cells. It inhibited the RANKL (receptor activator of nuclear factor-κB ligand)-induced upregulation of TRAP (tartrate-resistant acid phosphatase) activity as well as the formation of multinuclear osteoclasts. In addition, halenaquinone substantially suppressed RANKL-induced IκB degradation and Akt phosphorylation. Thus, these results suggest that halenaquinone inhibits RANKL-induced osteoclastogenesis at least by suppressing the NF-κB and Akt signaling pathways.
Collapse
Affiliation(s)
- Sachiko Tsukamoto
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan.
| | - Tomoharu Takeuchi
- Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
| | - Tetsuro Kawabata
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan
| | - Hikaru Kato
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan
| | - Michiko Yamakuma
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan
| | - Kanae Matsuo
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan
| | - Ahmed H El-Desoky
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan
| | - Fitje Losung
- Faculty of Fisheries and Marine Science, Sam Ratulangi University, Kampus Bahu, Manado 95115, Indonesia
| | - Remy E P Mangindaan
- Faculty of Fisheries and Marine Science, Sam Ratulangi University, Kampus Bahu, Manado 95115, Indonesia
| | - Nicole J de Voogd
- Naturalis Biodiversity Center, PO Box 9517, 2300 RA Leiden, The Netherlands
| | - Yoichiro Arata
- Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
| | - Hideyoshi Yokosawa
- School of Pharmacy, Aichi Gakuin University, Chikusa-ku, Nagoya 464-8650, Japan
| |
Collapse
|
10
|
Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs 2013; 31:1539-46. [PMID: 24114121 DOI: 10.1007/s10637-013-0029-6] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2013] [Accepted: 09/11/2013] [Indexed: 12/11/2022]
Abstract
BACKGROUND A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid tumors. METHODS Patients received vorinostat orally once daily on days 1-14 and bortezomib intravenously on days 1, 4, 8 and 11 of a 21-day cycle. Starting dose (level 1) was vorinostat (400 mg) and bortezomib (0.7 mg/m(2)). Bortezomib dosing was increased using a standard phase I dose-escalation schema. PKs were evaluated during cycle 1. RESULTS Twenty-three patients received 57 cycles of treatment on four dose levels ranging from bortezomib 0.7 mg/m(2) to 1.5 mg/m(2). The MTD was established at vorinostat 400 mg daily and bortezomib 1.3 mg/m(2). DLTs consisted of grade 3 fatigue in three patients (1 mg/m(2),1.3 mg/m(2) and 1.5 mg/m(2)) and grade 3 hyponatremia in one patient (1.5 mg/m(2)). The most common grade 1/2 toxicities included nausea (60.9%), fatigue (34.8%), diaphoresis (34.8%), anorexia (30.4%) and constipation (26.1%). Objective partial responses were observed in one patient with NSCLC and in one patient with treatment-refractory soft tissue sarcoma. Bortezomib did not affect the PKs of vorinostat; however, the Cmax and AUC of the acid metabolite were significantly increased on day 2 compared with day 1. CONCLUSIONS This combination was generally well-tolerated at doses that achieved clinical benefit. The MTD was established at vorinostat 400 mg daily × 14 days and bortezomib 1.3 mg/m(2) on days 1, 4, 8 and 11 of a 21-day cycle.
Collapse
Affiliation(s)
- William R Schelman
- University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, K6/568 CSC, Madison, WI, 53792, USA,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Bertrand J, Tennoune N, Marion-Letellier R, Goichon A, Chan P, Mbodji K, Vaudry D, Déchelotte P, Coëffier M. Evaluation of ubiquitinated proteins by proteomics reveals the role of the ubiquitin proteasome system in the regulation of Grp75 and Grp78 chaperone proteins during intestinal inflammation. Proteomics 2013; 13:3284-92. [PMID: 24030972 DOI: 10.1002/pmic.201300082] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2013] [Revised: 08/13/2013] [Accepted: 08/21/2013] [Indexed: 12/19/2022]
Abstract
The ubiquitin proteasome system (UPS) is the major pathway of intracellular protein degradation and may be involved in the pathophysiology of inflammatory bowel diseases or irritable bowel syndrome. UPS specifically degrades proteins tagged with an ubiquitin chain. We aimed to identify polyubiquitinated proteins during inflammatory response in intestinal epithelial HCT-8 cells by a proteomic approach. HCT-8 cells were incubated with interleukin 1β, tumor necrosis factor-α, and interferon-γ for 2 h. Total cellular protein extracts were separated by 2D gel electrophoresis and analyzed by an immunodetection using antiubiquitin antibody. Differential ubiquitinated proteins were then identified by LC-ESI MS/MS. Seven proteins were differentially ubiquitinated between control and inflammatory conditions. Three of them were chaperones: Grp75 and Hsc70 were more ubiquitinated (p < 0.05) and Grp78 was less ubiquitinated (p < 0.05) under inflammatory conditions. The results for Grp75 and Grp78 were then confirmed in HCT-8 cells and in 2-4-6-trinitrobenzen sulfonic acid induced colitis in rats mimicking inflammatory bowel disease by immunoprecipitation. No difference was observed in irritable bowel syndrome like model. In conclusion, we showed that a proteomic approach is suitable to identify ubiquitinated proteins and that UPS-regulated expression of Grp75 and Grp78 may be involved in inflammatory response. Further studies should lead to the identification of ubiquitin ligases responsible for Grp75 and Grp78 ubiquitination.
Collapse
Affiliation(s)
- Julien Bertrand
- INSERM Unit 1073, University of Rouen, Rouen, France; Institute for Research and Innovation in Biomedicine, University of Rouen, Rouen, France
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Imramovský A, Jorda R, Pauk K, Řezníčková E, Dušek J, Hanusek J, Kryštof V. Substituted 2-hydroxy-N-(arylalkyl)benzamides induce apoptosis in cancer cell lines. Eur J Med Chem 2013; 68:253-9. [DOI: 10.1016/j.ejmech.2013.08.009] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Revised: 07/31/2013] [Accepted: 08/01/2013] [Indexed: 12/11/2022]
|
13
|
Leung CH, Zhong HJ, Chan DSH, Ma DL. Bioactive iridium and rhodium complexes as therapeutic agents. Coord Chem Rev 2013. [DOI: 10.1016/j.ccr.2013.01.034] [Citation(s) in RCA: 234] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
14
|
Broad-spectrum antimalarial activity of peptido sulfonyl fluorides, a new class of proteasome inhibitors. Antimicrob Agents Chemother 2013; 57:3576-84. [PMID: 23689711 DOI: 10.1128/aac.00742-12] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Despite declining numbers of cases and deaths, malaria remains a major public health problem in many parts of the world. Today, case management relies heavily on a single class of antimalarial compounds: artemisinins. Hence, development of resistance against artemisinins may destroy current malaria control strategies. Beyond malaria control are elimination and eradication programs that will require drugs with good activity against acute infection but also with preventive and transmission-blocking properties. Consequently, new antimalarials are needed not only to ensure malaria control but also for elimination and eradication efforts. In this study, we introduce peptido sulfonyl fluorides (PSF) as a new class of compounds with antiplasmodial activity. We show that PSF target the plasmodial proteasome and act on all asexual stages of the intraerythrocytic cycle and on gametocytes. PSF showed activities at concentrations as low as 20 nM against multidrug-resistant and chloroquine-sensitive Plasmodium falciparum laboratory strains and clinical isolates from Gabon. Structural requirements for activity were identified, and cytotoxicity in human HeLa or HEK 293 cells was low. The lead PSF PW28 suppressed growth of Plasmodium berghei in vivo but showed signs of toxicity in mice. Considering their modular structure and broad spectrum of activity against different stages of the plasmodial life cycle, proteasome inhibitors based on PSF have a great potential for further development as preclinical candidate compounds with improved species-specific activity and less toxicity.
Collapse
|
15
|
Rentsch A, Landsberg D, Brodmann T, Bülow L, Girbig AK, Kalesse M. Synthese und Pharmakologie von Proteasom-Inhibitoren. Angew Chem Int Ed Engl 2013. [DOI: 10.1002/ange.201207900] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
16
|
Rentsch A, Landsberg D, Brodmann T, Bülow L, Girbig AK, Kalesse M. Synthesis and pharmacology of proteasome inhibitors. Angew Chem Int Ed Engl 2013; 52:5450-88. [PMID: 23526565 DOI: 10.1002/anie.201207900] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2012] [Indexed: 12/17/2022]
Abstract
Shortly after the discovery of the proteasome it was proposed that inhibitors could stabilize proteins which ultimately would trigger apoptosis in tumor cells. The essential questions were whether small molecules would be able to inhibit the proteasome without generating prohibitive side effects and how one would derive these compounds. Fortunately, "Mother Nature" has generated a wide variety of natural products that provide distinct selectivities and specificities. The chemical synthesis of these natural products finally provided access to analogues and optimized drugs of which two different classes have been approved for the treatment of malignancies. Despite these achievements, additional lead structures derived from nature are under investigation and will be discussed with regard to their biological potential and chemical challenges.
Collapse
Affiliation(s)
- Andreas Rentsch
- Institut für Organische Chemie and Centre of Biomolecular Drug Research, Leibniz Universität Hannover, Schneiderberg 1B, 30167 Hannover, Germany
| | | | | | | | | | | |
Collapse
|
17
|
Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system. Invest New Drugs 2012. [DOI: 10.1007/s10637-012-9902-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
18
|
Lansdell TA, Hewlett NM, Skoumbourdis AP, Fodor MD, Seiple IB, Su S, Baran PS, Feldman KS, Tepe JJ. Palau'amine and related oroidin alkaloids dibromophakellin and dibromophakellstatin inhibit the human 20S proteasome. JOURNAL OF NATURAL PRODUCTS 2012; 75:980-985. [PMID: 22591513 PMCID: PMC3367325 DOI: 10.1021/np300231f] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
We report herein that the oroidin-derived alkaloids palau'amine (1), dibromophakellin (2), and dibromophakellstatin (3) inhibit the proteolytic activity of the human 20S proteasome as well as the (i)20S immunoproteasome catalytic core. Palau'amine is found to prevent the degradation of ubiquitinylated proteins, including IκBα, in cell culture, which may be indicative of the potential mechanism by which these agents exhibit their exciting cytotoxic and immunosuppressive properties.
Collapse
Affiliation(s)
- Theresa A. Lansdell
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48823
| | - Nicole M. Hewlett
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48823
| | | | - Matthew D. Fodor
- Department of Chemistry, The Pennsylvania State University, University Park, PA 16802
| | - Ian B. Seiple
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037
| | - Shun Su
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037
| | - Phil. S. Baran
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037
| | - Ken S. Feldman
- Department of Chemistry, The Pennsylvania State University, University Park, PA 16802
| | - Jetze J. Tepe
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48823
| |
Collapse
|
19
|
Peroxisome proliferator-activated receptor-γ activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress. J Hypertens 2012; 30:315-26. [PMID: 22179086 DOI: 10.1097/hjh.0b013e32834f043b] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
AIMS Hypertension is associated with increased plasma inflammatory markers such as cytokines and increased vascular cyclooxygenase-2 (COX-2) expression. The ability of peroxisome proliferator-activated receptor-γ (PPARγ) agonists to reduce oxidative stress seems to contribute to their anti-inflammatory properties. This study analyzes the effect of pioglitazone, a PPARγ agonist, on interleukin-1β-induced COX-2 expression and the role of reactive oxygen species (ROS) on this effect. METHODS AND RESULTS Vascular smooth muscle cells from hypertensive rats stimulated with interleukin-1β (10 ng/ml, 24 h) were used. Interleukin-1β increased: 1) COX-2 protein and mRNA levels; 2) protein and mRNA levels of the NADPH oxidase subunit NOX-1, NADPH oxidase activity and ROS production; and 3) phosphorylation of inhibitor of nuclear factor kappa B (IκB) kinase (IKK) nuclear expression of the p65 nuclear factor kappa B (NF-κB) subunit and cell proliferation, all of which were reduced by apocynin (30 μmol/l). Interleukin-1β-induced COX-2 expression was reduced by apocynin, tempol (10 μmol/l), catalase (1000 U/ml) and lactacystin (5 μmol/l). Moreover, H2O2 (50 μmol/l, 90 min) induced COX-2 expression, which was reduced by lactacystin. Pioglitazone (10 μmol/l) reduced the effects of interleukin-1β on: 1) COX-2 protein and mRNA levels; 2) NOX-1 protein and mRNA levels, NADPH oxidase activity and ROS production; and 3) p-IKK, p65 expressions and cell proliferation. Pioglitazone also reduced the H2O2-induced COX-2 expression and increased Cu/Zn and Mn-superoxide dismutase protein expression. PPARγ small interfering RNA (5 nmol/l) further increased interleukin-1β-induced COX-2 and NOX-1 mRNA levels. In addition, pioglitazone increased the interleukin-1β-induced PPARγ mRNA levels. CONCLUSION PPARγ activation with pioglitazone reduces interleukin-1β-induced COX-2 expression by interference with the redox-sensitive transcription factor NF-κB.
Collapse
|
20
|
Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease. Vascul Pharmacol 2012; 57:41-7. [PMID: 22366375 DOI: 10.1016/j.vph.2012.02.005] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2011] [Revised: 02/09/2012] [Accepted: 02/10/2012] [Indexed: 01/04/2023]
Abstract
The transcription factor nuclear factor-κB (NF-κB) is a main regulator of the expression of several genes involved in the activation of inflammation, cell proliferation, cell immunity and apoptosis. Excess or inappropriate activation of NF-κB has been observed in human inflammatory diseases, including atherosclerosis. Because of the extensive involvement of NF-κB signaling in human diseases, efforts have been made in developing inhibitors of this pathway. Here we will provide an overview of the biology of NF-κB activation pathways. We will here especially focus on current knowledge of the role of the classical ("canonical") NF-κB activation pathway as a potential therapeutic target for anti-atherosclerotic therapies in clinical applications, and discuss classical and novel therapeutic strategies to reduce its prolonged activation.
Collapse
|
21
|
Lallemand B, Chaix F, Bury M, Bruyère C, Ghostin J, Becker JP, Delporte C, Gelbcke M, Mathieu V, Dubois J, Prévost M, Jabin I, Kiss R. N-(2-{3-[3,5-Bis(trifluoromethyl)phenyl]ureido}ethyl)-glycyrrhetinamide (6b): A Novel Anticancer Glycyrrhetinic Acid Derivative that Targets the Proteasome and Displays Anti-Kinase Activity. J Med Chem 2011; 54:6501-13. [DOI: 10.1021/jm200285z] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Benjamin Lallemand
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| | - Fabien Chaix
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| | - Marina Bury
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| | - Céline Bruyère
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| | - Jean Ghostin
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| | - Jean-Paul Becker
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| | - Cédric Delporte
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| | - Michel Gelbcke
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| | - Véronique Mathieu
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| | - Jacques Dubois
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| | - Martine Prévost
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| | - Ivan Jabin
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| | - Robert Kiss
- Laboratoire de Chimie Bioanalytique, Toxicologie et Chimie Physique Appliquée, ‡Laboratoire de Toxicologie, and #Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), and §Laboratoire de Chimie Organique and ⊥Laboratoire de Structure et Fonction des Membranes Biologiques, Faculté des Sciences, ULB, Brussels, Belgium
| |
Collapse
|
22
|
Xu D, Ondeyka J, Harris GH, Zink D, Kahn JN, Wang H, Bills G, Platas G, Wang W, Szewczak AA, Liberator P, Roemer T, Singh SB. Isolation, structure, and biological activities of Fellutamides C and D from an undescribed Metulocladosporiella (Chaetothyriales) using the genome-wide Candida albicans fitness test. JOURNAL OF NATURAL PRODUCTS 2011; 74:1721-1730. [PMID: 21761939 DOI: 10.1021/np2001573] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
In a whole-cell mechanism of action (MOA)-based screening strategy for discovery of antifungal agents, Candida albicans was used, followed by testing of active extracts in the C. albicans fitness test (CaFT), which provides insight into the mechanism of action. A fermentation extract of an undescribed species of Metulocladosporiella that inhibited proteasome activity in a C. albicans fitness test was identified. The chemical genomic profile of the extract contained hypersensitivity of heterozygous deletion strains (strains that had one of the genes of the diploid genes knocked down) of genes represented by multiple subunits of the 25S proteasome. Two structurally related peptide aldehydes, named fellutamides C and D, were isolated from the extract. Fellutamides were active against C. albicans and Aspergillus fumigatus with MICs ranging from 4 to 16 μg/mL and against fungal proteasome (IC₅₀ 0.2 μg/mL). Both compounds showed proteasome activity against human tumor cell lines, potently inhibiting the growth of PC-3 prostate carcinoma cells, but not A549 lung carcinoma cells. In PC-3 cells compound treatment produced a G2M cell cycle block and induced apoptosis. Preliminary SAR studies indicated that the aldehyde group is critical for the antifungal activity and that the two hydroxy groups are quantitatively important for potency.
Collapse
Affiliation(s)
- Deming Xu
- Department of Natural Products and Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Raja SM, Clubb RJ, Ortega-Cava C, Williams SH, Bailey TA, Duan L, Zhao X, Reddi AL, Nyong AM, Natarajan A, Band V, Band H. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther 2011; 11:263-76. [PMID: 21088503 DOI: 10.4161/cbt.11.2.13959] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The receptor tyrosine kinase ErbB2 is overexpressed in up to a third of breast cancers, allowing targeted therapy with ErbB2-directed humanized antibodies such as Trastuzumab. Concurrent targeting of ErbB2 stability with HSP90 inhibitors is synergistic with Trastuzumab, suggesting that pharmacological agents that can inhibit HSP90 as well as signaling pathways activated by ErbB2 could be useful against ErbB2-overexpressing breast cancers. The triterpene natural product Celastrol inhibits HSP90 and several pathways relevant to ErbB2-dependent oncogenesis including the NFκB pathway and the proteasome, and has shown promising activity in other cancer models. Here, we demonstrate that Celastrol exhibits in vitro antitumor activity against a panel of human breast cancer cell lines with selectivity towards those overexpressing ErbB2. Celastrol strongly synergized with ErbB2-targeted therapeutics Trastuzumab and Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol. Celastrol significantly retarded the rate of growth of ErbB2-overexpressing human breast cancer cells in a mouse xenograft model with only minor systemic toxicity. Mechanistically, Celastrol not only induced the expected ubiquitinylation and degradation of ErbB2 and other HSP90 client proteins, but it also increased the levels of reactive oxygen species (ROS). Our studies show that the Michael Acceptor functionality in Celastrol is important for its ability to destabilize ErbB2 and exert its bioactivity against ErbB2-overexpressing breast cancer cells. These studies suggest the potential use of Michael acceptor-containing molecules as novel therapeutic modalities against ErbB2-driven breast cancer by targeting multiple biological attributes of the driver oncogene.
Collapse
Affiliation(s)
- Srikumar M Raja
- Department of Medicine, Evanston Northwestern Healthcare Research Institute, Northwestern University, Evanston, IL, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
New therapies using novel mechanisms to induce tumor cell death are needed with plants playing a crucial role as a source for potential anticancer compounds. One highly promising class of natural compounds are the triterpenoids with betulinic acid (BetA) as the most prominent representative. In-vitro studies have identified this agent as potently effective against a wide variety of cancer cells, also those derived from therapy-resistant and refractory tumors, whereas it has been found to be relatively nontoxic for healthy cells. In-vivo preclinically applied BetA showed some remarkable anticancer effects and a complete absence of systemic toxicity in rodents. BetA also cooperated with other therapies to induce tumor cell death and several potent derivatives have been discovered. Its antitumor activity has been related to its direct effects on mitochondria where it induces Bax/Bak-independent cytochrome-c release.
Collapse
|
25
|
La Clair JJ. Natural product mode of action (MOA) studies: a link between natural and synthetic worlds. Nat Prod Rep 2010; 27:969-95. [DOI: 10.1039/b909989c] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
26
|
Lavelin I, Beer A, Kam Z, Rotter V, Oren M, Navon A, Geiger B. Discovery of novel proteasome inhibitors using a high-content cell-based screening system. PLoS One 2009; 4:e8503. [PMID: 20041034 PMCID: PMC2797363 DOI: 10.1371/journal.pone.0008503] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2009] [Accepted: 12/08/2009] [Indexed: 11/18/2022] Open
Abstract
The regulated degradation of damaged or misfolded proteins, as well as down-regulation of key signaling proteins, within eukaryotic and bacterial cells is catalyzed primarily by large, ATP-dependent multimeric proteolytic complexes, termed proteasomes. Inhibition of proteasomal activity affects a wide variety of physiological and pathological processes, and was found to be particularly effective for cancer therapy. We report here on the development of a novel high throughput assay for proteasome inhibition using a unique, highly sensitive live-cell screening, based on the cytoplasm-to-nucleus translocation of a fluorescent proteasome inhibition reporter (PIR) protein, consisting of nuclear localization signal-deficient p53 derivative. We further show here that mdm2, a key negative regulator of p53 plays a key role in the accumulation of PIR in the nucleus upon proteasome inhibition. Using this assay, we have screened the NCI Diversity Set library, containing 1,992 low molecular weight synthetic compounds, and identified four proteasome inhibitors. The special features of the current screen, compared to those of other approaches are discussed.
Collapse
Affiliation(s)
- Irena Lavelin
- Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Avital Beer
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - Zvi Kam
- Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Varda Rotter
- Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Moshe Oren
- Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Ami Navon
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - Benjamin Geiger
- Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
- * E-mail:
| |
Collapse
|